Matt Hollingsworth is the Chief Innovation Officer and Co-Founder of Carta Healthcare. He said there will be a growing need for technology in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Matt Hollingsworth said:
“Although the adoption of AI in healthcare is nothing new, there will continue to be a growing need for AI technology in 2024 and beyond. With an overall lack of manpower in healthcare, as seen in nursing and staff shortage trends, AI looks like the best solution for retaining existing manpower at competitive compensation rates while increasing efficiency in workflow and improving clinician job satisfaction. According to the National Library of Medicine, the key to successful AI implementation is to do it in a clinically relevant way that clinical caregivers can get behind. It's not only about the technology, it's about how technology and caregivers work together in a trusted way to believe in, train, and commit their AI solutions to provide long-term value.”
There is no one-size-fits-all AI solution for streamlining healthcare data, as each health institution has their own unique approach and associated needs. In 2024, health leaders should avoid generalized “AI platforms” with nebulous value and instead, take a more nuanced approach. Given the excessive hype around AI at the moment, health leaders should cut through the hype by selecting solutions that provide value-based/risk-bearing engagements as opposed to SaaS contracts; that will prevent health providers from bearing the risk of the technical execution. At this point, AI has reached a degree of maturity that should no longer require providers to take a bet on a technology with a multi-million dollar SaaS contract. Technology companies should put their money where their marketing is. A successful, tailored solution requires consultation with experts familiar with the intricacies of healthcare data to employ techniques such as brute force mapping to create a stable system, while adjusting the approach periodically to keep up with changes in technology and management.”
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More